Breast cancer 'tumour trigger' that spreads disease discovered

ConclusionAn Edinburgh-based team used mice engineered to develop breast cancer to better understand how it spreads from breast tissue to the lung, where it can be fatal. They identified specific chemical signals and receptors on immune cells called macrophages that were involved in the spread. By genetically tampering with one of the signalling pathways, they were able to reduce some of the cancer spread, raising hopes that this might be a future treatment avenue.Fiddling with the genetics in the same way as was done for the mice would probably not be a viable treatment for humans. Aside from ethical and technical issues, genetic manipulation of this nature could lead to a range of side effects. However, there are potentially other ways of blocking the same signalling pathway.The results were encouraging, but they are at a very early research stage. Right now, we don’t know if this would work in humans, because it has only been tested in mice. While biologically similar, mice and humans do differ in potentially important ways. The only way to know if disrupting this signalling pathway might be useful in minimising breast cancer spread to the lungs would be to do experiments on humans. We also don’t know if this treatment helped the mice live longer, experience less pain or respond better to other treatments. Similarly, the genetic manipulation didn’t stop the cancer spreading completely to the lungs, it just reduced it. Hence, we are a long way off stopping...
Source: NHS News Feed - Category: Consumer Health News Tags: Cancer Source Type: news

Related Links:

Opinion statementBisphosphonates are utilized routinely in breast cancer. In metastatic disease with bone involvement, bisphosphonates prevent or delay skeletal-related events and can improve pain control. Different agents have shown benefit compared with placebo or no treatment. While in unselected patients, comparison between zoledronic acid and pamidronate did not show a significant difference, exploratory analyses showed that in patients with osteolytic lesions or hypercalcemia, zoledronic acid is superior to pamidronate. De-escalating treatment with zoledronic acid from every 4 to every 12  weeks has been shown t...
Source: Current Treatment Options in Oncology - Category: Cancer & Oncology Source Type: research
Fight Aging! provides a weekly digest of news and commentary for thousands of subscribers interested in the latest longevity science: progress towards the medical control of aging in order to prevent age-related frailty, suffering, and disease, as well as improvements in the present understanding of what works and what doesn't work when it comes to extending healthy life. Expect to see summaries of recent advances in medical research, news from the scientific community, advocacy and fundraising initiatives to help speed work on the repair and reversal of aging, links to online resources, and much more. This content is...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
Conclusion: Estimating the burden of chronic toxicities should contribute to enhance rational decision-making on treatments including chemotherapy in patients with low versus high risk of recurrence.Breast Care
Source: Breast Care - Category: Cancer & Oncology Source Type: research
Publication date: Available online 13 December 2018Source: Journal of Geriatric OncologyAuthor(s): Andrea Sitlinger, Rebecca A. Shelby, Alyssa N. Van Denburg, Heidi White, Sarah N. Edmond, Paul K. Marcom, Hayden B. Bosworth, Francis J. Keefe, Gretchen G. KimmickAbstractObjectiveTo explore the impact of symptoms on physical function in women on adjuvant endocrine therapy for breast cancer.MethodsEligible women were postmenopausal, had hormone receptor positive, stage I-IIIA breast cancer, completed surgery, chemotherapy, radiation, and on adjuvant endocrine therapy. At a routine follow-up visit, women (N = 107) complete...
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
This article, however, is more of a commentary on high level strategy and the effects of regulation, coupled with a desire to forge ahead rather than hold back in the matter of treating aging, thus I concur with much more of what is said than is usually the case. For decades, one of the most debated questions in gerontology was whether aging is a disease or the norm. At present, excellent reasoning suggests aging should be defined as a disease - indeed, aging has been referred to as "normal disease." Aging is the sum of all age-related diseases and this sum is the best biomarker of aging. Aging and its d...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
People who have undergone chemotherapy or radiotherapy suffer a reduced life expectancy and increased risk of suffering other age-related conditions even when the cancer is defeated. These cancer therapies produce large numbers of senescent cells, both as a result of their toxicity and because they force cancerous cells into senescence. It is quite likely that this is the primary mechanism by which successful cancer treatments nonetheless shorten later lifespan. This could be considered a true form of accelerated aging, as the accumulation of senescent cells is one of the root causes of aging. These cells secrete signals t...
Source: Fight Aging! - Category: Research Authors: Tags: Daily News Source Type: blogs
AbstractObjectiveTo assess the effectiveness of Yishen Jiangu Granules ( 益肾健骨颗粒, YSJGG) on aromatase inhibitor-associated musculoskeletal symptoms (AIMSS).MethodsA single-arm, open-label study was conducted in 34 postmenopausal women with breast cancer who experienced AIMSS. Patients were treated with YSJGG for 12 weeks (12.4 g orally twice daily). The primary outcome was a change in the mean worst pain score of Brief Pain Inventory-Short Form (BPI-SF) over 12 weeks, and the second outcomes included changes in pain severity and pain-related interference of BPI-SF and Western Ontario and McMaster Universities Os...
Source: Chinese Journal of Integrative Medicine - Category: Internal Medicine Source Type: research
ConclusionsWhile QoL in disease-free breast cancer survivors 5  years post-diagnosis was largely comparable to the general population on average, still many survivors suffered from adverse effects. There appears to be a need for ongoing screening and support regarding fatigue, sleep problems, cognitive problems, arthralgia/pain, menopausal/sexual symptoms, phy sical performance, and weight problems during and several years following breast cancer therapy.
Source: Quality of Life Research - Category: Health Management Source Type: research
CONCLUSION Cognitive impairment can affect daily functioning, quality of life, and capacity to work in patients with cancer and those in remission. Consequently, cognitive assessment is now an important and necessary part of a comprehensive oncological care plan. Cancer-related cognitive impairment might be due to the direct effects of the cancer itself, nonspecific factors, or comorbid conditions that are independent of the disease and/or due to the adverse effects of the treatment or combination of treatments given for the disease. The prevalence and extent of cognitive impairment associated with cancer is recognized but...
Source: Innovations in Clinical Neuroscience - Category: Neuroscience Authors: Tags: Cognition Current Issue Neuro oncology Neurology Review cancer chemotherapy cognitive impairment neuropsychological assessment treatment Source Type: research
ConclusionsOverall, women with MBC receiving first-line endocrine therapy have a good QOL. The addition of palbociclib to letrozole maintains health-related QOL and improves pain scores in treatment-na ïve postmenopausal patients with ER+/HER2− MBC compared with letrozole alone. Significantly greater delay in deterioration of health-related QOL was observed in patients without progression versus those who progressed and in patients with an objective response versus non-responders.ClinicalTrials .gov: NCT01740427 (https://clinicaltrials.gov/ct2/show/NCT01740427)
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Biochemistry | Biology | Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Genetics | Grants | Health | Laboratory Medicine | Medical Ethics | Pain | Science | Study | Women